Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP)

Preexposure prophylaxis (PrEP) has emerged as a major tool in the prevention of HIV infection. Appropriate use of once-daily emtricitabine 200  mg and tenofovir disoproxil fumarate 300 mg (Truvada®; Gilead, Foster City, CA) in combination with safer sex activities significantly reduces the risk of HIV infection. Trials initially supported efficacy of PrEP in adults, prompting its approval for adult use by the U.S. Food and Drug Administ ration (FDA) in July 2012 (Gilead, 2018). Due to growing data suggesting PrEP as beneficial in preventing HIV in high-risk adolescents, the FDA approved it for prevention of HIV in this patient population in May 2018 (Gilead, 2018; Smart + Strong, 2018).

Source: Journal of the Association of Nurses in AIDS Care - June 12, 2018 Category: Nursing Authors: Christopher W. Blackwell Tags: Practice Brief Source Type: research